v3.25.2
STOCKHOLDERS’ EQUITY (Details Narrative) - USD ($)
$ / shares in Units, $ in Thousands
 3 Months Ended 12 Months Ended
Feb. 10, 2025
Jun. 30, 2025
Jun. 30, 2024
Mar. 31, 2025
Apr. 16, 2025
Oct. 11, 2024
Nov. 03, 2022
Accumulated Other Comprehensive Income (Loss) [Line Items]              
Unrecognized stock-based compensation expense   $ 200 $ 300        
2013 Beyond Air Equity Incentive Plan [Member]              
Accumulated Other Comprehensive Income (Loss) [Line Items]              
Stock option shares authorized for issuance   830,000       150,000  
Number of shares available for grant   46,372          
Weighted average fair value of options   $ 5.89          
Weighted average remaining contractual term       7 years 10 months 24 days      
2013 Beyond Air Equity Incentive Plan [Member] | Restricted Stock Units (RSUs) [Member]              
Accumulated Other Comprehensive Income (Loss) [Line Items]              
Weighted average remaining service period   1 year 3 months 18 days          
2013 BA Plan [Member]              
Accumulated Other Comprehensive Income (Loss) [Line Items]              
Unrecognized stock-based compensation expense   $ 700          
2013 BA Plan [Member]              
Accumulated Other Comprehensive Income (Loss) [Line Items]              
Weighted average remaining service period   1 year 8 months 12 days          
Unrecognized stock-based compensation expense   $ 4,100          
Weighted average fair value of options   $ 3.23          
2021 Beyond Cancer Ltd Equity Incentive Plan [Member]              
Accumulated Other Comprehensive Income (Loss) [Line Items]              
Stock option shares authorized for issuance   4,000,000         2,000,000
Number of shares available for grant   1,588,000          
Weighted average fair value of options            
Stock option vesting term, description   The vesting terms of the options issued under the 2021 BC Plan are generally four years and they expire ten years from the grant date.          
Stock option vesting term   10 years          
Weighted average remaining contractual term   6 years 10 months 24 days   7 years 2 months 12 days      
2021 BC Plan [Member]              
Accumulated Other Comprehensive Income (Loss) [Line Items]              
Unrecognized stock-based compensation expense   $ 1,600          
Weighted average remaining contractual term   1 year 3 months 18 days          
2023 Neuro Nos Ltd Equity Incentive Plan [Member]              
Accumulated Other Comprehensive Income (Loss) [Line Items]              
Stock option shares authorized for issuance         1,525,000    
Number of shares available for grant   146,296          
Weighted average remaining service period   1 year 9 months 18 days          
Unrecognized stock-based compensation expense   $ 400          
Weighted average fair value of options   $ 3.00          
Weighted average remaining contractual term   8 years 6 months   9 years      
Weighted average fair value of options   $ 2.38          
Minimum [Member] | Beyond Cancer Ltd [Member] | Common Stock [Member]              
Accumulated Other Comprehensive Income (Loss) [Line Items]              
Fair value per share   $ 3.00          
2025 ATM [Member]              
Accumulated Other Comprehensive Income (Loss) [Line Items]              
Common stock sales proceeds $ 35,000            
Ownership percentage 2.50%            
Sale of net proceeds   $ 2,400          
Number of shares issued in transaction   564,699          
2025 ATM [Member] | Maximum [Member]              
Accumulated Other Comprehensive Income (Loss) [Line Items]              
Sale of net proceeds   $ 5,800